Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Blenrep |
|---|---|
| Manufacturer | GlaxoSmithKline GmbH & Co.KG |
| Prescription required | Yes |
Blenrep polvo,1vial x 100mg (belantamab mafodotin)
belantamab mafodotin
Description
Blenrep polvo,1vial x 100mg (belantamab mafodotin) is a medicine catalog record in the MediPriceHub database. Active ingredient: belantamab mafodotin. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: GlaxoSmithKline GmbH & Co.KG. Therapeutic category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Pack information: 100, 1. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.How to Use
Use belantamab mafodotin under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: belantamab mafodotin. Pack size: 100, 1. Pack unit: bottle. Manufacturer: GlaxoSmithKline GmbH & Co.KG. Origin country: Spain. Source category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.This information is for reference only. Consult a qualified healthcare professional before using any medicine.